Skip to main content

Table 2 Changes in iron-metabolism indices after initiation of roxadustat

From: Roxadustat alleviates the inflammatory status in patients receiving maintenance hemodialysis with erythropoiesis-stimulating agent resistance by increasing the short-chain fatty acids producing gut bacteria

Time

Ferritin (ng/mL)

SI (umol/L)

TIBC (umol/L)

UIBC (umol/L)

TS (%)

STfR (mg/L)

Hepcidin (ng/L)

Baseline (M0)

72.96 ± 14.16

15.72 ± 6.21

56.70 ± 10.83

41.49 ± 14.00

27.85 ± 12.20

38.46 ± 7.75

116.12 ± 17.46

M1

65.69 ± 12.00

16.63 ± 7.64

54.59 ± 8.65

37.97 ± 12.35

31.62 ± 15.82

41.63 ± 7.57

86.72 ± 16.97

M3

55.54 ± 13.73

15.47 ± 5.23

48.93 ± 12.97

33.46 ± 13.92

33.58 ± 14.99

50.18 ± 7.73

78.86 ± 15.90

F value

10.73

0.489

5.906

3.721

1.582

18.68

1034.523

P value

< 0.001

0.602

0.005

0.032

0.218

< 0.001

< 0.001

  1. M0: before roxadustat; M1: 1 month after initiation of roxadustat; M3: 3 months after initiation of roxadustat (end of study)